Thus, treatment-naïve advanced NSCLC patients were treated with pembrolizumab monotherapy if PD-L1 expression was 50% or higher from 2016 or immunochemotherapy in any case from 2018. This evidence concerns the gene CD274 and non-small cell lung carcinoma.